Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer

被引：0

作者：

G Hofstetter

A Berger

E Schuster

A Wolf

G Hager

I Vergote

I Cadron

J Sehouli

E I Braicu

S Mahner

P Speiser

C Marth

A G Zeimet

H Ulmer

R Zeillinger

N Concin

机构：

[1] Innsbruck Medical University,Department of Gynecology and Obstetrics

[2] Molecular Oncology Group,Department of Obstetrics and Gynecology

[3] Medical University of Vienna,Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology

[4] Universitaire Ziekenhuzen Leuven,Department of Gynecology

[5] Katholieke Universiteit Leuven,Department of Gynecology and Gynecologic Oncology

[6] European Competence Center for Ovarian Cancer,Department of Medical Statistics

[7] Campus Virchow Klinikum,undefined

[8] Charité – Universitätsmedizin Berlin,undefined

[9] University Medical Center Hamburg-Eppendorf,undefined

[10] Informatics,undefined

[11] and Health Economics,undefined

[12] Innsbruck Medical University,undefined

来源：

British Journal of Cancer | 2011年 / 105卷

关键词：

ovarian cancer; delta133p53; p53 isoforms; p53; p73;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1593 / 1599

页数：6

共 50 条

[31] The significance of p53 isoform expression in serous ovarian cancer
Chambers, Setsuko K.
Martinez, Jesse D.
FUTURE ONCOLOGY, 2012, 8 (06) : 683 - 686
[32] Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study
Havrilesky, L
Darcy, KM
Hamdan, H
Priore, RL
Leon, J
Bell, J
Berchuck, A
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (20) : 3814 - 3825
[33] Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors
Gershenson, DM
Deavers, M
Diaz, S
Tortolero-Luna, G
Miller, BE
Bast, RC
Mills, GB
Silva, EG
CLINICAL CANCER RESEARCH, 1999, 5 (12) : 4053 - 4058
[34] p53 mutation as a prognostic marker in advanced laryngeal carcinoma
Bradford, CR
Zhu, S
Poore, J
Fisher, SG
Beals, TF
Thoraval, D
Hanash, SM
Carey, TE
Wolf, GT
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 1997, 123 (06) : 605 - 609
[35] p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage
M Aoubala
F Murray-Zmijewski
M P Khoury
K Fernandes
S Perrier
H Bernard
A-C Prats
D P Lane
J-C Bourdon
Cell Death & Differentiation, 2011, 18 : 248 - 258
[36] p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage
Aoubala, M.
Murray-Zmijewski, F.
Khoury, M. P.
Fernandes, K.
Perrier, S.
Bernard, H.
Prats, A-C
Lane, D. P.
Bourdon, J-C
CELL DEATH AND DIFFERENTIATION, 2011, 18 (02): : 248 - 258
[37] The RNA helicase p68 modulates expression and function of the Δ133 isoform(s) of p53, and is inversely associated with Δ133p53 expression in breast cancer
H C Moore
L B Jordan
S E Bray
L Baker
P R Quinlan
C A Purdie
A M Thompson
J-C Bourdon
F V Fuller-Pace
Oncogene, 2010, 29 : 6475 - 6484
[38] The RNA helicase p68 modulates expression and function of the Δ133 isoform(s) of p53, and is inversely associated with Δ133p53 expression in breast cancer
Moore, H. C.
Jordan, L. B.
Bray, S. E.
Baker, L.
Quinlan, P. R.
Purdie, C. A.
Thompson, A. M.
Bourdon, J-C
Fuller-Pace, F. V.
ONCOGENE, 2010, 29 (49) : 6475 - 6484
[39] p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer
Kudahetti, Sak
Fisher, Gabrielle
Ambroisine, Laurence
Foster, Christopher
Reuter, Victor
Eastham, James
Moller, Henrik
Kattan, Michael W.
Cooper, Colin S.
Scardino, Peter
Cuzick, Jack
Berney, Daniel M.
BJU INTERNATIONAL, 2009, 104 (01) : 20 - 24
[40] Clinical trials with p53 tumor suppressor gene for p53-mutant ovarian cancer
Pegram, MD
Runnebaum, I
Buekers, T
Konecny, G
Karlan, BY
Chan, D
Slamon, DJ
Horowitz, J
Buller, R
EUROPEAN JOURNAL OF CANCER, 1999, 35 : S33 - S33

← 1 2 3 4 5 →